Corinne de Vries
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Corinne de Vries has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Sam Schoenmakers
European Medicines Agency, Amsterdam, The Netherlands
2 shared publications A Caputi
Policlinico Universitario, Messina
1 shared publicationA Gatta
Padua University Hospital, Padua
1 shared publicationAlexandra Ganev
University of Rome La Sapienza, Rome, Italy
1 shared publication- Alexandra Ganev
Sapienza University of Rome Rome Italy
1 shared publication - Alison Nightingale
Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Unintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?
Pregnant and breastfeeding individuals are routinely excluded from clinical drug development, creating persistent evidence gaps in pharmacology, safety, and dosing. Despite mandatory contraception and pregnancy testing, unintended pregnancies occur, particularly during the development of central nervous system (CNS) medicines used by women of reproductive age. Once exposure to an investigational medicinal product (IMP) has occurred, these pregnancies may provide valuable prospective human data; however, treatment or trial participation is often discontinued and follow‐up may be incomplete. This study assessed how unintended pregnancies and breastfeeding data were reported, managed, and evaluated in clinical trials supporting marketing authorization applications (MAAs) for CNS products. We reviewed 35 MAAs for centrally authorized CNS products submitted to the European Medicines Agency between 2012 and 2022. Pregnancy frequency, IMP exposure, pregnancy outcomes, breastfeeding data and regulatory comments were extracted from MAA dossiers, Day 120 Lists of Questions and Summaries of Product Characteristics. Overall, 451 pregnancies were identified, including 343 with IMP exposure. Of these, 108 occurred in pivotal phase 3 trials, resulting in 39 live births, 23 elective terminations, 17 spontaneous pregnancy losses, and 29 unknown or ongoing outcomes. Regulators raised 19 pregnancy‐related and six breastfeeding‐related concerns. Only one dossier included a dedicated human lactation study. Pregnancy reporting varied substantially in location, format and case‐level detail, while 27% of pivotal IMP‐exposed pregnancies had unknown or ongoing outcomes at assessment. More structured reporting and follow‐up, including relevant exposure and pharmacokinetic data where feasible, could strengthen clinical pharmacology and regulatory evidence and support more informative product information.
- 22 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Open AccessUnintended Pregnancies and Breastfeeding Studies during Central Nervous System Drug Development: How Are they Handled, Is There Room for Improvement?
Pregnant and breastfeeding individuals are routinely excluded from clinical drug development, creating persistent evidence gaps in pharmacology, safety, and dosing. Despite mandatory contraception and pregnancy testing, unintended pregnancies occur, particularly during the development of central nervous system (CNS) medicines used by women of reproductive age. Once exposure to an investigational medicinal product (IMP) has occurred, these pregnancies may provide valuable prospective human data; however, treatment or trial participation is often discontinued and follow‐up may be incomplete. This study assessed how unintended pregnancies and breastfeeding data were reported, managed, and evaluated in clinical trials supporting marketing authorization applications (MAAs) for CNS products. We reviewed 35 MAAs for centrally authorized CNS products submitted to the European Medicines Agency between 2012 and 2022. Pregnancy frequency, IMP exposure, pregnancy outcomes, breastfeeding data and regulatory comments were extracted from MAA dossiers, Day 120 Lists of Questions and Summaries of Product Characteristics. Overall, 451 pregnancies were identified, including 343 with IMP exposure. Of these, 108 occurred in pivotal phase 3 trials, resulting in 39 live births, 23 elective terminations, 17 spontaneous pregnancy losses, and 29 unknown or ongoing outcomes. Regulators raised 19 pregnancy‐related and six breastfeeding‐related concerns. Only one dossier included a dedicated human lactation study. Pregnancy reporting varied substantially in location, format and case‐level detail, while 27% of pivotal IMP‐exposed pregnancies had unknown or ongoing outcomes at assessment. More structured reporting and follow‐up, including relevant exposure and pharmacokinetic data where feasible, could strengthen clinical pharmacology and regulatory evidence and support more informative product information.
- Open Access
- 13 August 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (11) , 1820-1823
EMA perspective on the value of model‐informed drug development for labeling recommendations regarding medicine use during pregnancy and breastfeeding
- 13 August 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (11) , 1820-1823
Open AccessEMA perspective on the value of model‐informed drug development for labeling recommendations regarding medicine use during pregnancy and breastfeeding
- Open Access
- 19 June 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (11) , 1127-1136
Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance
Introduction There is a need to strengthen the evidence base regarding medication use during pregnancy and to facilitate the early detection of safety signals. EudraVigilance (EV) serves as the primary system for managing and analysing information concerning suspected adverse drug reactions (ADRs) within the European Economic Area. Despite its various functionalities, the current format for electronic submissions of safety reports lacks a specific data element indicating medicine exposure during pregnancy. Objective This paper aims to address the limitations of existing approaches by developing a rule-based algorithm in EV that more reliably identifies cases that are truly representative of an ADR during pregnancy. Methods The study utilised the standardised MedDRA query (SMQ) 'Pregnancy and neonatal topics' (PNT) as a benchmark for comparison. Recognising that the SMQ PNT also retrieves healthy pregnancy outcomes, contraceptive failure, failed abortifacients as well as ADRs not associated with pregnancy, a novel algorithm was tailored to improve the accuracy of identifying suspected ADRs occurring during pregnancy. Results Upon testing, the algorithm demonstrated superior performance, correctly predicting 90% of cases reporting an ADR during pregnancy, compared to 54% achieved by the SMQ PNT. The implementation of the algorithm in EV led to the retrieval of 202,426 cases. Conclusion The development and successful testing of the novel algorithm represents a step forward in pregnancy-specific signal detection in EV. Because signals associated with pregnancy may be diluted in a large database such as EV, this study lays the groundwork for future research to evaluate the effectiveness of disproportionality methods on a more refined subset of pregnancy-related ADR reports.
- 19 June 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (11) , 1127-1136
Open AccessIdentification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance
Introduction There is a need to strengthen the evidence base regarding medication use during pregnancy and to facilitate the early detection of safety signals. EudraVigilance (EV) serves as the primary system for managing and analysing information concerning suspected adverse drug reactions (ADRs) within the European Economic Area. Despite its various functionalities, the current format for electronic submissions of safety reports lacks a specific data element indicating medicine exposure during pregnancy. Objective This paper aims to address the limitations of existing approaches by developing a rule-based algorithm in EV that more reliably identifies cases that are truly representative of an ADR during pregnancy. Methods The study utilised the standardised MedDRA query (SMQ) 'Pregnancy and neonatal topics' (PNT) as a benchmark for comparison. Recognising that the SMQ PNT also retrieves healthy pregnancy outcomes, contraceptive failure, failed abortifacients as well as ADRs not associated with pregnancy, a novel algorithm was tailored to improve the accuracy of identifying suspected ADRs occurring during pregnancy. Results Upon testing, the algorithm demonstrated superior performance, correctly predicting 90% of cases reporting an ADR during pregnancy, compared to 54% achieved by the SMQ PNT. The implementation of the algorithm in EV led to the retrieval of 202,426 cases. Conclusion The development and successful testing of the novel algorithm represents a step forward in pregnancy-specific signal detection in EV. Because signals associated with pregnancy may be diluted in a large database such as EV, this study lays the groundwork for future research to evaluate the effectiveness of disproportionality methods on a more refined subset of pregnancy-related ADR reports.
- Open Access
- 1 February 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (2) , 283-288
Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap
- 1 February 2021
- Published by Elsevier in Drug Discovery Today
- Vol. 26 (2) , 283-288
Open AccessStrengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap
- Open Access
P73 Preliminary results of the Study of Acute Liver Transplant (SALT): NSAID exposure and risk of acute liver failure leading to transplantation in 7 European countries
Introduction: The risk of acute liver failure (ALF) related to NSAIDs is still discussed and the European Medicines Agency requested a study investigating this. University Bordeaux Segalen conducted the study independently. Aim: To estimate the incidence rates of ALF leading to registration for liver transplantation (LT) in patients exposed to NSAIDs. Method: Multinational, multicentre, case-population study performed in France, Greece, Ireland, Italy, the Netherlands, Portugal, and the UK retrospectively evaluating a 3-year period (2005–2007) in adults. Data of ALF cases were sought through liver transplant registries and hospital records. Demographic and clinical data were collected for all ALF cases and drug use information was collected for the exposure window of 30 days prior to index date (ID, initial symptoms of liver disease). For ALF cases exposed to NSAIDs (ATC code M01A), rate per million treatment-years (tt-yrs) was calculated using sales data from IMS. Poisson CIs (95% CI) were estimated. Results: In the seven participating countries, 62 LT centres were identified and contacted, five were excluded (four paediatric, one oncology), and 50 actively contributed data before database lock. Among the 8824 patients identified from LT lists for the period 2005–2007, 500 were cases of ALF: 197 with identified clinical cause, 21 with incomplete or unavailable medical files, and 241 drug-exposed without identified clinical cause. Among the latter, 34 were exposed to at least one NSAID, 123 exposed to other drugs, and 84 were acute drug intoxications. Mean age of NSAID-exposed ALF cases was 43.8 years, 24 were female. Event rates per million treatment-years were 4.4 (95% CI 3.0 to 6.1) for all NSAIDs pooled, 5.6 (2.4 to 11.1) for nimesulide (8 cases), 5.8 (2.8 to 10.6) for ibuprofen (10 cases), 4.5 (1.5 to 10.4) for diclofenac (5 cases), and 4.7 (1.0 to 13.6) for ketoprofen (3 cases). 71 of the 157 non-intoxication cases had been exposed to paracetamol (9.8 per million treatment-years, 95% CI 7.7 to 12.4), and 83 of the 84 intoxications. Conclusion: In seven countries over 3 years only 34 NSAID-exposed ALF cases leading to registration for LT were identified with no differences in incidence rates per million tt-yrs among the most used NSAIDs. Non-overdose paracetamol-associated liver failure was twice more common.
Open AccessP73 Preliminary results of the Study of Acute Liver Transplant (SALT): NSAID exposure and risk of acute liver failure leading to transplantation in 7 European countries
Introduction: The risk of acute liver failure (ALF) related to NSAIDs is still discussed and the European Medicines Agency requested a study investigating this. University Bordeaux Segalen conducted the study independently. Aim: To estimate the incidence rates of ALF leading to registration for liver transplantation (LT) in patients exposed to NSAIDs. Method: Multinational, multicentre, case-population study performed in France, Greece, Ireland, Italy, the Netherlands, Portugal, and the UK retrospectively evaluating a 3-year period (2005–2007) in adults. Data of ALF cases were sought through liver transplant registries and hospital records. Demographic and clinical data were collected for all ALF cases and drug use information was collected for the exposure window of 30 days prior to index date (ID, initial symptoms of liver disease). For ALF cases exposed to NSAIDs (ATC code M01A), rate per million treatment-years (tt-yrs) was calculated using sales data from IMS. Poisson CIs (95% CI) were estimated. Results: In the seven participating countries, 62 LT centres were identified and contacted, five were excluded (four paediatric, one oncology), and 50 actively contributed data before database lock. Among the 8824 patients identified from LT lists for the period 2005–2007, 500 were cases of ALF: 197 with identified clinical cause, 21 with incomplete or unavailable medical files, and 241 drug-exposed without identified clinical cause. Among the latter, 34 were exposed to at least one NSAID, 123 exposed to other drugs, and 84 were acute drug intoxications. Mean age of NSAID-exposed ALF cases was 43.8 years, 24 were female. Event rates per million treatment-years were 4.4 (95% CI 3.0 to 6.1) for all NSAIDs pooled, 5.6 (2.4 to 11.1) for nimesulide (8 cases), 5.8 (2.8 to 10.6) for ibuprofen (10 cases), 4.5 (1.5 to 10.4) for diclofenac (5 cases), and 4.7 (1.0 to 13.6) for ketoprofen (3 cases). 71 of the 157 non-intoxication cases had been exposed to paracetamol (9.8 per million treatment-years, 95% CI 7.7 to 12.4), and 83 of the 84 intoxications. Conclusion: In seven countries over 3 years only 34 NSAID-exposed ALF cases leading to registration for LT were identified with no differences in incidence rates per million tt-yrs among the most used NSAIDs. Non-overdose paracetamol-associated liver failure was twice more common.
- 23 June 2009
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 85 (9) , 808
Regarding the need, or lack thereof, of a comparator group for pregnancy registries
- 23 June 2009
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 85 (9) , 808
Regarding the need, or lack thereof, of a comparator group for pregnancy registries